Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer

Yue Xi,Ting Li,Yun Xi,Xinyi Zeng,Ying Miao,Rui Guo,Min Zhang,Biao Li
DOI: https://doi.org/10.1186/s12935-022-02681-0
IF: 6.429
2022-09-02
Cancer Cell International
Abstract:Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer and is susceptible to develop gemcitabine (GEM) resistance. Decreased expression of human equilibrative nucleoside transporter 1 (hENT1) accompanied by compensatory increase of glycolysis is strongly associated with GEM resistance in TNBC. In this study, we investigated the treatment feasibility of combined hENT1 upregulation and miR-143-mediated inhibition of glycolysis for reversing GEM resistance in TNBC.
oncology
What problem does this paper attempt to address?